Express & Expedited Shipping Service
USD $79.56
AustraliaNexGard SPECTRA Chews is an all-in-one oral treatment for small dogs weighing between 3.6 and 7.5 kilograms. It provides comprehensive protection against fleas, ticks, heartworm, and intestinal worms.
NexGard SPECTRA works by combining two active ingredients, Afoxolaner and Milbemycin Oxime. Afoxolaner targets and eliminates fleas and ticks, while Milbemycin Oxime provides protection against heartworm and intestinal parasites.
Administer NexGard SPECTRA once a month. Ensure your dog consumes the entire chew. It can be given with or without food.
NexGard SPECTRA is intended for small dogs only. Consult a veterinarian before use if your dog has a history of seizures or other medical conditions. Keep out of reach of children and other pets.
Side effects are rare but may include vomiting, diarrhea, lethargy, and loss of appetite. If any unusual symptoms occur, contact your veterinarian immediately.
Yes, a prescription from a licensed veterinarian is required to purchase NexGard SPECTRA.
NexGard SPECTRA offers a convenient and effective solution for protecting your small dog from a wide range of parasites. Its palatable chewable form makes it easy to administer, ensuring your pet remains healthy and parasite-free.
Health Guides
Nov 06, 2026
Medication dry mouth happens when a drug reduces saliva production or alters the sensation of moisture. Anticholinergic effects are a common cause, and management usually combines a medication review, moisture replacement and tooth protection. Persistent dryness can make eating or speaking difficult
Nov 05, 2026
Blood pressure medicines can cause dizziness on standing because they reduce the body's ability to maintain pressure against gravity. The resulting drop can briefly reduce blood flow to the brain, a condition called orthostatic hypotension. Blood pressure medication dizziness often appears after t
Nov 04, 2026
Biotin supplements can interfere with thyroid and heart blood tests, producing falsely high or unexpectedly low results. This interference affects certain laboratory methods rather than the actual hormone or cardiac-marker concentration being measured. The greatest danger is a falsely low troponin r
Nov 02, 2026
ADHD medication monitoring tracks blood pressure, heart rate, body mass, appetite and sleep before treatment, during dose adjustments and throughout long-term care. For adults, NICE recommends pulse and blood pressure checks before and after each dose change, then every six months. The aim is to pre
Nov 01, 2026
Baricitinib safety depends on infection screening, blood tests, and prompt evaluation of new symptoms. The main concerns are serious infections, shingles, blood clots, cancer, and cardiovascular events. Blood counts, liver and kidney function, and cholesterol help guide treatment. Historical rheumat
Oct 31, 2026
Whether to repeat a dose of an oral medication depends on the medicine, formulation, and elapsed time. Vomiting within 15 minutes or seeing an intact tablet can justify considering a replacement; after an hour, another dose is usually unnecessary. These are general timing guides, not permission to r
Oct 30, 2026
Tacrolimus monitoring measures the tacrolimus level in whole blood to help balance organ rejection prevention against drug-related toxic effects. The result is useful only when interpreted against the dose and formulation. A routine trough sample is collected immediately before the next dose, usuall
Oct 29, 2026
Serotonin syndrome is a potentially life-threatening drug reaction caused by excessive serotonin activity. Fever, confusion, and muscle jerking after a medicine change require urgent medical assessment. Symptoms often begin within hours, particularly when medicines with overlapping serotonin effects
Oct 28, 2026
Lithium monitoring combines timed blood levels with kidney, thyroid, and calcium tests to keep bipolar treatment effective and reduce toxicity risk. Testing starts before treatment and continues throughout it. Lithium has a narrow therapeutic index, so relatively small changes in blood concentration
Oct 27, 2026
Benign prostatic hyperplasia (BPH) is a noncancerous enlarged prostate. Alpha blockers ease urinary symptoms by relaxing muscle around the outlet, often within days to weeks. 5-alpha-reductase inhibitors (5-ARIs) shrink the prostate gradually and can reduce the risks of urinary retention and surgery
